Lillys Diabetes Drugs Meet Endpoints In Phase Iii Studies | Latest News RSS feed

Lillys Diabetes Drugs Meet Endpoints In Phase Iii Studies - Latest News

Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies

Eli Lilly and Company LLY along with Boehringer Ingelheim announced positive top-line data from two clinical studies – EASE 2 and EASE 3 – from the phase III EASE program evaluating SGLT2 inhibitor, J... read more

Diabetes Market: Eli Lilly's Classic Pharma Vs. Sanofi Aventis' Modern Synergy

Pipelines don't always equal profits, however, as Lilly well understands. After failing to meet clinical ... are diabetes-related drugs, with eight in phase II trials or better. Two of the products ar... read more

Sanofi to discontinue phase III studies of iniparib & otamixaban as drugs fail to meet endpoints

The randomized phase III ECLIPSE trial of iniparib in squamous non-small cell lung cancer (Sq NSCLC) did not meet its primary endpoint. In the study ... seven growth platforms: diabetes solutions, hum... read more

Looking for another news?

EMA reviews Lilly/BI diabetes drug 'similar' to Lantus

The investigational long-acting insulin is similar to Lantus (insulin glargine), Sanofi's biggest-selling drug; in the first-quarter, its sales leapt 19.7% to 1.34 billion euros. Lilly ... Phase III s... read more

Lilly's Alzheimer Drug Fails Phase III Study, Stock Down

Lilly ... in late-stage trials. Top-line data on solanezumab from two phase III EXPEDITION studies conducted on patients with mild-to-moderate Alzheimer's disease were announced back in Aug 2012. Sola... read more

2 Diabetes Growth Stocks And 1 Moonshot To Hold Through 2025

HbA1c measures blood glucose over 90 days, and is the primary endpoint of virtually all pivotal trials ... so Eli Lilly has much to celebrate going into the next decade. An added plus is that Lilly ha... read more

AstraZeneca, Eli Lilly end phase III clinical trials of Alzheimer drug - AstraZeneca and Eli Lilly said Tuesday they would discontinue the global phase III clinical ... unlikely to meet their primary endpoints and should be stopped. The decision to st... read more

Eli Lilly's basal insulin peglispro shows HbA1c superiority against Lantus in phase III trials with type 1 diabetics

"Lilly is committed to meeting the diverse needs of people living with diabetes who need therapies that will help them meet ... Phase III trials are expected to be disclosed in 2015. Lilly plans to su... read more

Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study

The series of setbacks continues for Eli Lilly and Company LLY as the company announced that its phase III JUNIPER ... The study did not meet its primary endpoint of overall survival. However, it show... read more

Merck's Diabetes Drug Meets Primary Endpoint in Key Studies

Data from the studies showed that ertugliflozin, when added to Januvia or metformin, led to A1C (a measure of average blood glucose) reduction in patients with type II diabetes. The drug met the key s... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us